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Abstract
Background: This study reports on the analysis of the application and diagnostic predictability of the revised 2014
ICBD criteria in an unselected cohort of UK patients, and the ensuing organ associations and patterns of disease.
Methods: A retrospective cohort study was conducted using a database of electronic medical records. Three
categories were recognised: clinically defined BD, incomplete BD and rejected diagnoses of BD. We applied the ISG
1990 and ICBD 2014 classification criteria to these subgroups to validate diagnostic accuracy against the
multidisciplinary assessment.
Results: Between 2012 and 2015, 281 patients underwent initial assessment at an urban tertiary care centre: 190
patients with a confirmed diagnosis of BD, 7 with an incomplete diagnosis, and 84 with a rejected diagnosis.
ICBD 2014 demonstrated an estimated sensitivity of 97.89% (95% CI: 94.70 to 99.42) and positive likelihood ratio
of 1.21 (1.10 to 1.28). The strongest independent predictors were: Central nervous lesions (OR = 10.57, 95% CI: 1.34
to 83.30); Genital ulceration (OR = 9.05, 95% CI: 3.35 to 24.47); Erythema nodosum (OR = 6.59, 95% CI: 2.35 to 18.
51); Retinal vasculitis (OR = 6.25, 95% CI: 1.47 to 26.60); Anterior uveitis (OR = 6.16, 95% CI: 2.37 to 16.02); Posterior
uveitis (OR = 4.82, 95% CI: 1.25 to 18.59).
Conclusions: The ICBD 2014 criteria were more sensitive at picking up cases than ISG 1990 using the
multidisciplinary assessment as the gold standard. ICBD may over-diagnose BD in a UK population. Patients
who have an incomplete form of BD represent a distinct group that should not be given an early diagnostic
label. Behçet’s disease is a complex disease that is best diagnosed by multidisciplinary clinical assessment.
Patients in the UK differ in their clinical presentation and genetic susceptibility from the original descriptions.
This study also highlights an incomplete group of Behçet’s patients that are less well defined by their clinical
presentation.
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Background
Behçet’s disease (BD) is a complex multisystem auto-
inflammatory disorder, which in its classic form, presents
with recurrent oral aphthous ulcers, genital ulcers, and
uveitis. Its aetiology is unknown but likely involves
interplay between genetic and environmental factors
[1]. BD has a very heterogeneous and unpredictable
phenotype with the potential to involve the cardiovas-
cular, renal, gastrointestinal, pulmonary, vascular, mus-
culoskeletal, urological and central nervous systems to
varying degrees [2–4].
Behçet’s disease is more common, and often more
severe, along the ancient Silk Road, which extended
from eastern Asia to the Mediterranean [5, 6]. It is most
common in Turkey (80 to 370 cases per 100,000) [6],
while the prevalence is much lower in Northern European
and North American populations (1 per 15,000 to 1 per
500,000) [7]. The first symptoms often occur in young
adults between 20 and 40 years of age but it is also
infrequently seen in children. Familial clustering has been
reported, although most cases of Behçet’s are thought to
be sporadic in onset [8, 9].
As there is no universally accepted pathognomonic
test for BD, diagnosis is based on the recognition of a
particular but variable group of clinical manifestations.
In 1990, these features were incorporated into the
International Study Group (ISG) diagnostic/classifica-
tion criteria based on data from a computer analysis of
914 patients with BD and 308 diseased controls with
clinical features mimicking those of BD [10]. Although
these were originally intended for the definition of pa-
tients participating in research programmes, they have
since been shown to perform well in a clinical context
and may be helpful in establishing a diagnosis [11].
More recent evaluations of the ISG collaboration have
found lower sensitivity when compared to other classi-
fication criteria, leading to an initiative to develop
newer criteria. In 2014, an international team from 27
countries (not including the UK) described the new
International Criteria for Behçet’s disease (ICBD), cap-
able of “performing with good discriminatory potential
regardless of country” and being “intuitive and easy to
use in a wide variety of settings”. In comparison to the
earlier ISG criteria, the ICBD 2014 criteria included
both vascular and neurological features, and assigned
more points for the presence of oral or genital aphtho-
sis and ocular findings. In the published evaluation,
the newly proposed criteria exhibited much improved
sensitivity over the older widely accepted ISG criteria
while maintaining specificity. As a result, it was pro-
posed that these revised criteria could be used as a
tool for mass screening and identification of possible
Behçet’s patients in different clinical settings. The au-
thors attempted to standardise and define a group of
patients who had definite disease, and contrast these
with patients who had fewer clinical manifestations
and were unlikely to have Behçet’s [12].
Here we report on the application and performance of
both the ISG and ICBD criteria to a cohort of unselected
patients referred to the Birmingham Behçet’s Syndrome
National Centre of Excellence since its inception in July
2012 to July 2015. The clinic was established in 1990
and has traditionally adopted a multidisciplinary ap-
proach to the management of patients with BD [13].
The aim of the study was to determine the frequency
distribution of clinical characteristics for patients with
clinically confirmed BD, possible but unlikely (termed
‘incomplete’) BD and a rejected diagnosis of BD. We
compared the ISG and ICBD points-based scoring
criteria with the gold standard multidisciplinary clinical
assessment process (a core feature of our service design)
to determine the probability of BD in our UK-based
cohort, and reviewed the potential impact of the applica-
tion of the new classification system as a screening tool
for new referrals to the service. We investigated how
many patients, who presented with typical clinical fea-
tures of BD, would be reclassified if the newer ICBD
2014 classification criteria were employed.
Methods
This was a retrospective study of an unselected incep-
tion cohort in a tertiary referral centre. It was con-
ducted in accordance with the Declaration of Helsinki,
and approved by the local Trust Research and Develop-
ment team and The London-Westminster Research Ethics
Committee. Informed consent, including that from a re-
sponsible legal guardian in certain instances, was obtained
from all patients before their details were entered onto the
electronic database.
Data collection
All patients seen at the Birmingham Centre of Excellence
for Behçet’s disease since the Centre’s inception in July
2012 until July 2015 were recruited consecutively. Data
were obtained from the in-house database for all 281
patients irrespective of disease duration. Patients’ clinical
and demographic characteristics were collected and
summarised, so as to discern local patterns of disease.
With respect to pathergy, we assigned a total score based
on the result of any formal testing as well as reported
reaction, as this phenomenon is not currently routinely
assessed in a UK population.
Patient diagnosis was established at the time of first
presentation following multidisciplinary combined clin-
ical assessment. Clinicians involved in this assessment
included specialists in Rheumatology, Ophthalmology,
Oral Medicine, Gynaecology, and where appropriate
Gastroenterology and Dermatology, after review of the
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referral information and pre-clinic contact with the pa-
tient. Diagnoses were made collaboratively following in-
dependent specialist assessment. Three categories were
recognised: clinically defined BD, incomplete BD and
rejected diagnoses of BD. The groups were analysed
separately to determine clinically defining or discrimin-
ating features. Patients who were classified as incom-
plete BD were felt to represent an interesting category,
demonstrating some features consistent with but not
necessarily diagnostic of BD, and not needing systemic
disease modifying therapies at the time of assessment.
Patients who presented with some clinical features of
BD but were believed to have an alternative diagnosis
were classified as a rejected group and usually dis-
charged from follow up. We applied the ISG 1990 and
ICBD 2014 classification criteria to these subgroups to
validate diagnostic accuracy against the gold standard
multi-disciplinary assessment process in our UK based
cohort. A selection of cases were subsequently analysed
in more detail: those who were clinically diagnosed fol-
lowing multidisciplinary review but nevertheless went
on to meet the newer ICBD 2014 criteria. We com-
pared variables between those patients who were newly
classified as BD by ICBD with those in the BD group
who were not reclassified.
Statistical analysis
All statistical analyses were conducted using IBM SPSS
Statistics for Windows, Version 22.0 (Armonk, NY:
IBM Corp.). Levels of continuous variables were
expressed as means ± standard deviations. Continuous
variables were compared between the categories of dis-
ease using a one-way analysis of variance with Tukey’s
Honestly Significant Difference test, and categorical
variables were compared with Fisher’s exact test. Diag-
nostic accuracies of ISG 1990 and ICBD 2014 criteria
were represented by sensitivities, specificities, and like-
lihood ratios, where patients in the incomplete group
were excluded from analysis. Odds ratios were obtained
from a multivariable logistic regression analysis among
variables with P values ≤ 0.05 in univariable analyses.
For all statistical evaluations, P values ≤ 0.05 were
considered to indicate statistical significance.
Results
A total of 281 patients were analysed: 190 patients with a
confirmed diagnosis of BD, 7 with an incomplete diagno-
sis, and 84 with a rejected diagnosis following multispeci-
alty clinical evaluation. Table 1 displays demographic data
for the patient groups.
One-way analysis of variance indicated that the mean
age of the three groups was significantly different. Post-
hoc Tukey’s Honestly Significant Difference test also
showed that the mean age was significantly different
between the BD and rejected groups (P < 0.001). The
proportion of males was not significantly different
between the groups (P = 0.205, Fisher’s exact test),
Table 1 Patient characteristics according to clinical diagnosis
Overall
(n = 281)
BD
(n = 190)
Incomplete BD
(n = 7)
Rejected diagnosis
(n = 84)
Age (years, mean +/− SD) 41.27 ± 13.63 43.42 ± 12.08 34.43 ± 7.50 36.99 ± 16.04
Age category (%)
< 14
14–18
19–25
26–30
31–40
41–50
51–60
61–70
71–80
81–90
1 (0.4)
10 (3.6)
23 (8.2)
28 (10.0)
79 (28.1)
70 (24.9)
47 (16.7)
18 (6.4)
4 (1.4)
1 (0.4)
0 (0)
2 (0.7)
9 (3.2)
20 (7.1)
55 (19.6)
48 (17.1)
40 (14.2)
13 (4.6)
3 (1.1)
0 (0)
0 (0)
0 (0)
2 (0.7)
0 (0)
3 (1.1)
2 (0.7)
0 (0)
0 (0)
0 (0)
0 (0)
3 (1.1)
8 (2.9)
12 (4.3)
8 (2.9)
19 (6.8)
20 (7.1)
7 (2.5)
5 (1.8)
1 (0.4)
1 (0.4)
Sex, male (N (%)) 98 (34.9) 72 (25.6) 3 (1.1) 23 (8.2)
Ethnicity (N (%))
Arab
Asian – Indian subcontinent
Black African
Black Caribbean
Chinese
Greek
Italian
Maori
White/Black Caribbean
White British
Unspecified
4 (1.4)
21 (7.5)
2 (1.1)
2 (0.7)
8 (2.9)
1 (0.4)
1 (0.4)
1 (0.4)
172 (61.2)
66 (23.5)
2 (0.7)
4 (1.42)
20 (7.1)
2 (1.1)
2 (0.7)
7 (2.5)
0 (0)
1 (0.4)
1 (0.4)
123 (43.8)
27 (9.6)
2 (0.7)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
5 (1.8)
2 (0.7)
0 (0)
0 (0)
1 (0.4)
0 (0)
0 (0)
1 (0.4)
1 (0.4)
0 (0)
0 (0)
44 (15.7)
37 (13.2)
0 (0)
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however for ethnicity the three groups differed signifi-
cantly (P = 0.002, Fisher’s exact test).
Forty-two of the 281 cases failed to meet ISG 1990 cri-
teria; 38 of these went on to meet the newer ICBD 2014
criteria (reclassified). Twenty-six cases were classified as
BD by the ISG criteria but were not confirmed clinically,
all of whom were in the rejected diagnosis group; this
increased to 68 cases for the ICBD 2014 criteria. The 16
patients who were both clinically and ICBD negative
were given alternative diagnoses based on clinical assess-
ment. These included ocular toxoplasmosis, vesicobullous
autoimmune diseases, inflammatory bowel disease, Sweet’s
syndrome, idiopathic aphthous ulceration, nutritional and
dietary deficiencies, and potential auto-inflammatory syn-
dromes. All of the seven patients who were categorised as
having incomplete BD exhibited oral ulcers, along with
various other clinical manifestations that included: acnei-
form rash, pseudofolliculitis, non-specific arthralgia, in-
flammatory arthritis, enthesopathy, fibromyalgia, chronic
diarrhoea and peripheral neuropathy. In addition, none of
these patients satisfied either the ISG 1990 or ICBD 2014
criteria.
A comparison of the ISG 1990 and ICBD 2014 criteria
and subsequent diagnostic accuracies compared with the
gold standard clinical diagnoses are displayed in Table 2.
The Receiver Operating Characteristic (ROC) curve
was calculated for the 2014 criteria in the study popula-
tion (0–9 cut-off points; n = 274) (Fig. 1). The area under
the ROC curve (AUC) was 0.818.
The frequencies of individual clinical features accord-
ing to diagnosis are shown in Table 3. The majority of
patients referred to the Behçet’s service had recurrent
oro-genital aphthous ulceration, however three of the
patients with confirmed BD did not present with oral
ulcers; all of these had significant inflammatory eye
disease that was typical of BD.
All the statistically significant variables above remained
significant when entered together into a multivariable
binary logistic regression model:
Genital ulceration P < 0.001: Odds ratio 9.05 with
95% confidence interval 3.35 to 24.47; Anterior uveitis
P < 0.001: Odds ratio 6.16 with 95% confidence interval
2.37 to 16.02; Posterior uveitis P = 0.022: Odds ratio 4.82
with 95% confidence interval 1.25 to 18.59; Erythema
nodosum P < 0.001: Odds ratio 6.59 with 95% confidence
interval 2.35 to 18.51; Retinal vasculitis P = 0.013: Odds
ratio 6.25 with 95% confidence interval 1.47 to 26.60;
Central nervous lesions P = 0.025: Odds ratio 10.57 with
95% confidence interval 1.34 to 83.30.
Thirty-eight patients were given a clinical diagnosis of
BD based on multidisciplinary clinical assessment and
met the ICBD but not the earlier ISG criteria. Table 4
represents a comparison between those patients in the
BD group who were reclassified based on ICBD and
those who were not. The reclassified patients exhibited
higher vascular and neurological scores.
Discussion
Our data shares some similarities with that obtained
from the development of the new multinational classifi-
cation scheme for BD [12]. In our cohort, ICBD 2014
demonstrated an estimated sensitivity of 97.89% (95%
CI: 94.70 to 99.42), compared to 94.8% (95% CI: 93.40
to 95.9) quoted in the original validation set, consider-
ably higher than that of the ISG 1990 criteria (77.89%).
We found a positive likelihood ratio of 1.21 (1.10 to
1.28). Nevertheless, we measured the specificity of
ICBD 2014 to be much lower than that revealed in the
original data set (19.05% (11.30 to 29.08), compared
with 90.5% (95% CI: 87.9 to 92.8%). The reason for this
discrepancy is that, in the new classification, a score of
four can be achieved solely with the presence of oro-
genital ulcers; however following clinical assessment
patients were often diagnosed with an alternative ex-
planation for their ulcers, such as idiopathic or post-
infectious aetiology, which would have given rise to
higher false positive rates. This is supported by the
finding that the symptoms showing the highest fre-
quency but the least discriminatory utility in our cohort
were oral and genital ulcers.
There were three patients who were diagnosed with
BD on clinical grounds but did not report classic recur-
rent oral aphthosis; all of these were diagnosed follow-
ing identification of characteristic ophthalmic changes
of panuveitis and retinal vasculitis. These patients
would not have satisfied the earlier ISG 1990 criteria
for diagnosing BD given the lack of recurrent oral
ulcers; however it is recognised that ocular disease may
be the initial manifestation in about 20% of cases. In
one series, anterior uveitis was present in 59% of cases,
posterior uveitis was present in 76% of cases, and panu-
veitis was present in 88.1% of cases [14]. Since there is
no pathognomonic clinical sign or laboratory test to
distinguish BD from other uveitic causes, the diagnosis
must be made based on characteristic ocular and systemic
Table 2 Diagnostic accuracy of ISG 1990 and ICBD 2014 criteria
in Birmingham cohort
ISG (95% CI) ICBD (95% CI)
Sensitivity 77.9% (71.3 to 83.6) 97.9% (94.7 to 99.4)
Specificity 69.1% (58.0 to 78.7) 19.1% (11.3 to 29.1)
Positive Likelihood ratio 2.52 (1.85 to 3.53) 1.21 (1.10 to 1.28)
Negative Likelihood ratio 0.32 (0.24 to 0.43) 0.11 (0.03 to 0.34)
Disease prevalence 69.3% (63.5 to 74.8) 69.3% (63.5 to 74.8)
Positive Predictive Value 85.1% (78.9 to 90.0) 73.2 (67.3 to 78.6)
Negative Predictive Value 58.0 (47.7 to 67.8) 80.0 (56.3 to 94.3)
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findings in the absence of evidence of other disease
that can explain the findings. This has led some to
develop diagnostic or classification criteria, for use in
the uveitis community, that rely on a minimum num-
ber and/or combination of clinical findings to identify
Behçet’s disease [15].
The incomplete group, described in the original com-
bined testing and validation sets of the ICBD criteria as
those with ‘possible but unlikely BD’, demonstrated
undisputed presence of oral ulcers (100%), along with
several skin and thrombotic manifestations. Patients in
this group were predominantly female. The authors be-
lieve that these patients form an interesting subgroup,
which should ideally be monitored for the development
of more specific target organ associations but should not
be given a diagnostic label due to uncertainty about
progression and treatment. None of the patients in the
incomplete group were started on systemic immuno-
modulatory therapies. In the reclassification group,
more patients were female, and central nervous system
lesions appeared statistically predictive for the develop-
ment of BD. Peripheral nervous system lesions also
showed a trend towards redefining disease according to
the newer criteria. There was no history of pathergy
nor was it observed on testing in all patients in this
group.
Behçet’s disease, like most other rheumatic diseases,
lacks a gold-standard test with a high degree of sensitiv-
ity and specificity, making it necessary to develop classi-
fication and diagnostic criteria to guide researchers and
clinicians. Classification criteria are designed to define a
homogenous population with similar clinical features
suitable for research studies. They are essential for our
understanding of disease pathogenesis, treatments out-
comes, for entry into clinical trials, and as such, increase
the specificity for underlying disease while at the same
time lose sensitivity on Receiver Operating Characteris-
tic (ROC) curve analysis. Conversely, the goal of diag-
nostic criteria is to have a high sensitivity and positive
predictive value (PPV) so as not to exclude individuals
with possible disease. The specificity and PPV of ICBD
was considerably lower than ISG in this cohort, which
reflects the degree of false positive cases referred to the
service and falsely thought to have BD. These indices are
Fig. 1 The receiver operator curve and sensitivity and specificity for the ICBD criteria
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likely to be even more truncated in local Rheumatology
centres where the prevalence of true BD is far lower. For
these reasons, it is important for criteria to be tailored
to the practice setting and clinicians to formulate a diag-
nosis based on sound clinical judgement and experience
in rare conditions.
To further understand how “universal” classification
criteria can be employed in individual clinical settings,
one should appreciate the role of Bayes’ theorem, named
after the 18th century English statistician, philosopher
and minister. It states that the odds of having a disease
is equal to the pre-test odds multiplied by the likelihood
ratio; the former being determined by the prevalence in
the population and the latter by the sensitivity and speci-
ficity in the data set [16]. Both types of criteria are highly
dependent on the disease prevalence in the patient
population being investigated. Bayes informs us that a
set of criteria can only be accurately applied to the
cohort for which it was designed. In light of this, it is
important to realise that there are important genotypic
and phenotypic variations in disease expression between
different populations in BD.
The genetic locus most widely studied in BD is the hu-
man leukocyte antigen (HLA) complex on chromosome
6p21. Disease susceptibility has consistently been associ-
ated with polymorphisms in the HLA-B gene, particu-
larly HLA-B*51 [17]. A recent meta-analysis showed a
significant increase in the risk of HLA-B*51 carriers to
develop BD compared with non-carriers across multiple
geographic locations [18]. Nevertheless, the HLA-B*51
association is not invariable: the relative risk of disease
with this haplotype is known to be stronger in Turkish,
Middle Eastern, and Japanese populations than in
Caucasians [19], and ethnic differences are thought to
have a major impact on clinical expression of BD [20].
More recently, Caucasian patients from the UK have
also been found to express HLA-B*57, another suscepti-
bility gene that carries a relative risk of disease equiva-
lent to that of HLA-B*51 [21]. Other HLA alleles may
also increase or decrease the risk for Behçet’s in various
populations and in men and women [22–25]. Moreover,
in a UK population, pathergy reaction is a relatively rare
phenomenon when tested for [26]. There are likely to be
further gender-specific differences such as those identi-
fied by the German Adamantiades Behcet’s disease regis-
try data [27]. These findings deserve greater attention to
define the exact biological and clinical profiles of both
true and incomplete Behçet’s in the UK in case they rep-
resent distinct pathobiological entities that are separate
from the classic Silk Road descriptions. Our study re-
vealed a low proportion of patients from both Turkish
and Middle Eastern ethnic groups, which reflects the
demography of Birmingham.
This study has several strengths: This is the first time
that the application and diagnostic predictability of the
newer ICBD 2014 classification criteria have been inves-
tigated for clinical use in a cohort of patients referred to
a National Behçet’s Centre in the UK. The patients re-
ferred to the service represent an unselected cohort,
which arguably assesses a set of discriminatory criteria
Table 3 Frequencies of individual clinical features according to clinical diagnosis
BD
(n = 190) (%)
Incomplete BD
(n = 7) (%)
Rejected diagnosis
(n = 84) (%)
P-valuea
Oral aphthosis 187 (98.4) 7 (100.0) 80 (95.2) 0.206
Genital aphthosis 161 (84.7) 0 (0) 58 (69.0) 0.005
Anterior uveitis 83 (43.7) 0 (0) 12 (14.3) <0.001
Posterior uveitis 54 (28.4) 0 (0) 3 (3.6) <0.001
Erythema nodosum 49 (25.8) 0 (0) 5 (6.0) <0.001
Acneiform lesions 42 (22.1) 2 (28.6) 16 (19.0) 0.632
Pseudofolliculitis 41 (21.6) 1 (14.3) 10 (11.9) 0.065
Retinal vasculitis 33 (17.4) 0 (0) 4 (4.8) 0.004
Pathergy test positivity 23 (12.1) 0 (0) 7 (7.1) 0.408
Large vein thrombosis 21 (11.1) 1 (14.3) 4 (4.8) 0.114
Central nervous lesion 18 (9.5) 0 (0) 1 (1.2) 0.010
Arterial thrombosis 8 (4.2) 1 (14.3) 1 (1.2) 0.283
Skin aphthosis 7 (3.7) 0 (0) 0 (0) 0.104
Phlebitis 5 (2.6) 0 (0) 0 (0) 0.328
Superficial thrombophlebitis 5 (2.6) 0 (0) 0 (0) 0.328
Peripheral nervous lesion 3 (1.6) 1 (14.3) 1 (1.2) 1.000
aUsing Fisher’s exact test
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in a more accurate and real-time manner than selecting
out a control group beforehand with other final diagno-
ses. Our data compare the classification criteria against
the conventional clinical diagnosis, and depicts the rate
of reclassification in patients who presented with clinical
manifestations but did not fulfil the previous classifica-
tion criteria. This study goes further in defining a rela-
tively under-recognised group of ‘incomplete’ patients
who appear to have an undifferentiated inflammatory
condition but who do not currently exhibit sufficient
diagnostic certainty for BD. Future research may help to
further understand the biological factors that are relevant
for these patients.
Our study has some limitations. Firstly, it was retro-
spective and conducted at a single time point, implying
that it is difficult to be certain about future development
of clinically defining features or severity of disease over
time. Secondly, the ophthalmic indicators of BD may
have been over-represented in our cohort as our hospital
is an internationally renowned tertiary referral centre for
uveitis.
Conclusions
In summary, the in-house data collection system linked
to the electronic medical records enabled effective evalu-
ation and investigation of the Birmingham National
Behçet’s Centre of Excellence to be undertaken. As
expected, the proposed ICBD 2014 criteria were more
sensitive at picking up cases than ISG 1990 using the
multidisciplinary clinical assessment process as the gold
standard. Specificity was less than expected for both
criteria but particularly so for ICBD, as in our hands
certain clinical features were not always judged to be
attributable to a BD diagnosis and gave rise to high false
positive values, though time and future follow-ups are
likely to improve performance. ICBD may serve as a use-
ful validated screening tool for BD but in our hands in a
predominantly UK population, appears to over-diagnose
BD. The gold standard for diagnosis should remain the
multidisciplinary clinical assessment, and if criteria are
to be used to assist with diagnosis, then we would
suggest reverting back to the older ISG 1990 criteria
until a more suitable alternative can be validated for use
in a UK population. This study also highlights the need
for further international harmonisation on potential
geographic variations in BD clinical presentations. Fu-
ture research may wish to investigate the revised ICBD
criteria in all three UK National Behçet’s Centres.
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